Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab in Recurrent and Metastatic Adenoid Cystic Carcinoma
NCT05074940Phase 2Active, not recruiting
- Start
- Aug 2022
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab in adenoid cystic carcinoma (ACC). Started Aug 2022; status: active, not recruiting.
02
Drugs
amivantamab
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT05074940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05074940.